PEPTIDE GUARDIANResearch literacy for peptides

Guides

Legal status tracker

The rules around peptides changed several times in 2026. This page puts the status of every compound on this site in one list, with the record each line comes from.

Public records from 2026

  • 30 October 2026. The US health department (HHS) published a notice in the Federal Register of a draft policy on pharmacy compounding of certain peptides. The policy is a draft and is not binding. Its appendix names six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Source: govinfo.gov
  • 21 September 2026. The World Anti-Doping Agency published its 2027 Prohibited List, in force from 1 January 2027. Its section on non-approved substances now gives peptides as a named example. Source: wada-ama.org
  • 14 May 2026. The FDA updated its list of substances nominated for pharmacy compounding, sorted by category. Source: fda.gov
  • 22 April 2026. Date of the current version of the FDA page on bulk drug substances that may present significant safety risks in compounding. It lists several peptides. Source: fda.gov

This is a summary of public records, not legal advice. Rules differ by country and change. Each compound page gives the full history with dates.

  • 5-Amino-1MQ

    Animal and cell studies only

    FDA statusNot approved. Not on any compounding list. FDA warned a compounder in January 2026 for using it. Source: fda.gov (dated 2026-01-20)

    In sportNot named on the List; S0 applies if it has no approval anywhere. WADA

  • AOD-9604

    Early human trials

    FDA statusNot FDA-approved. Not compoundable under the 503A list; FDA advisers voted 12-0 against adding it in 2024. Source: fda.gov (dated 2026-04-22)

    In sportProhibited at all times (class S2.2.3, growth hormone fragments). WADA

  • BPC-157

    Early human trials

    FDA statusNot approved. Not on the pharmacy compounding list. Named in a draft federal policy (30 October 2026) that is not an approval. Source: govinfo.gov (dated 2026-10-30)

    In sportProhibited at all times; named in class S0 (non-approved substances), 2026 and 2027. WADA

  • Cagrilintide

    Late-stage human trials

    FDA statusNo approval found anywhere. Novo Nordisk filed CagriSema with FDA in December 2025; no decision found yet. Source: fda.gov (dated 2026-10-01)

    In sportNot named; with no approval found anywhere, S0 applies: prohibited at all times. WADA

  • CJC-1295

    Early human trials

    FDA statusNot approved. Advisory committee voted against allowing it for pharmacy compounding. Source: fda.gov (dated 2026-04-22)

    In sportProhibited at all times; named in S2.2.4 (growth hormone releasing factors), 2026 and 2027. WADA

  • DSIP

    Early human trials

    FDA statusNot approved. FDA proposed not allowing compounding. Not in the October 2026 federal draft policy. Source: fda.gov (dated 2026-04-22)

    In sportNot named; unapproved, so it falls under class S0, prohibited at all times. WADA

  • Epithalon

    Early human trials

    FDA statusNot approved. FDA staff advised against compounding; a draft HHS policy would tolerate limited compounding. Source: govinfo.gov (dated 2026-10-30)

    In sportNot named; unapproved substances fall under class S0, prohibited at all times. WADA

  • GHK-Cu

    Early human trials

    FDA statusNot an approved drug. Cosmetic ingredient. Only non-injectable GHK-Cu is in Category 1 for compounding. Source: fda.gov (dated 2026-05-14)

    In sportNot named; S0 applies if it has no approval anywhere; none found. WADA

  • Glutathione

    Early human trials

    FDA statusNot FDA-approved. In FDA's Category 1 (under evaluation) for compounding; a 2022 proposal to exclude it is undecided. Source: fda.gov (dated 2026-05-14)

    In sportNot named on the 2026 or 2027 list; large IV infusions are a prohibited method. WADA

  • HGH fragment 176-191

    Animal and cell studies only

    FDA statusNot FDA-approved. Not on any FDA compounding category list or HHS's 2026 draft peptide list. Source: fda.gov (dated 2026-05-14)

    In sportProhibited at all times; named in WADA class S2.2.3 as 'hGH 176-191'. WADA

  • IGF-1 LR3

    Animal and cell studies only

    FDA statusNot approved. Not on FDA's compounding lists. Sold only as a research reagent. Source: fda.gov (dated 2026-04-22)

    In sportProhibited at all times; IGF-1 and its analogues are named in S2.3 (growth factors). WADA

  • Ipamorelin

    Early human trials

    FDA statusNot approved. Not on the pharmacy compounding list. FDA flags it as a significant safety risk. Source: fda.gov (dated 2026-04-22)

    In sportProhibited at all times; named in S2.2.4 as a growth hormone secretagogue. WADA

  • Kisspeptin

    Early human trials

    FDA statusNot approved anywhere. FDA lists kisspeptin-10 as a compounding substance that may present significant safety risks. Source: fda.gov (dated 2026-04-22)

    In sportProhibited at all times for male athletes; named in S2.2.1, 2026 and 2027. WADA

  • KPV

    Animal and cell studies only

    FDA statusNot approved. Not on the pharmacy compounding list. Named in a draft federal policy of 30 October 2026. Source: fda.gov (dated 2026-04-22)

    In sportNot named; no approval found anywhere, so S0 applies: prohibited at all times. WADA

  • MOTS-c

    Animal and cell studies only

    FDA statusNot approved. Not on the pharmacy compounding list. Named in a draft federal policy, 30 October 2026. Source: govinfo.gov (dated 2026-10-30)

    In sportProhibited at all times; named in S4.4.1 as an AMPK activator, 2026 and 2027. WADA

  • NAD+

    Early human trials

    FDA statusNot an FDA-approved drug. In FDA's Category 1 (under evaluation) for compounding; a 2019 proposal to exclude it is unfinished. Source: fda.gov (dated 2026-05-14)

    In sportNot named. S0 applies only if unapproved everywhere (unchecked). Large intravenous infusions are prohibited. WADA

  • PT-141 (bremelanotide)

    Approved medicine

    FDA statusApproved prescription medicine (Vyleesi) for low desire in premenopausal women only. Online "PT-141" is unapproved. Source: dailymed.nlm.nih.gov (dated 2026-11-09)

    In sportNot named on the 2026 or 2027 Prohibited List; no WADA ruling found. WADA

  • Retatrutide

    Late-stage human trials

    FDA statusNot approved. Investigational drug in phase 3 trials. Source: fda.gov (dated 2026-10-01)

    In sportNot named; with no approval found anywhere, S0 applies: prohibited at all times. WADA

  • Selank

    Early human trials

    FDA statusNot FDA-approved. Nomination for compounding withdrawn; not in the October 2026 federal draft policy. Source: fda.gov (dated 2026-04-22)

    In sportNot named. S0 status unclear because of its reported Russian registration. WADA

  • Semaglutide

    Approved medicine

    FDA statusApproved prescription medicine (Ozempic, Rybelsus, Wegovy). Compounded, salt-form and research-use versions are not FDA-approved. Source: fda.gov (dated 2026-10-01)

    In sportNot prohibited; approved, so outside S0. On the WADA Monitoring Program since 2024. WADA

  • Semax

    Early human trials

    FDA statusNot FDA-approved; registered in Russia. FDA staff opposed compounding; an October 2026 HHS draft policy covers nasal use. Source: hhs.gov (dated 2026-10-30)

    In sportNot named on the List; status unsettled since it is a registered medicine in Russia. WADA

  • SS-31 (elamipretide)

    Approved medicine

    FDA statusFDA-approved (accelerated) only for Barth syndrome, as Forzinity. SS-31 sold online is an unapproved drug. Source: dailymed.nlm.nih.gov (dated 2026-11-11)

    In sportNot named on 2026 or 2027 Lists; FDA approval keeps it outside S0. WADA

  • TB-500 (thymosin beta-4)

    Animal and cell studies only

    FDA statusNot approved. Not on the pharmacy compounding list. Source: fda.gov (dated 2026-05-14)

    In sportProhibited at all times; named in S2.3 (growth factors), 2026 and 2027. WADA

  • Tesamorelin

    Approved medicine

    FDA statusApproved prescription medicine (Egrifta) for HIV-related belly fat only. Research-use versions sold online are unapproved. Source: dailymed.nlm.nih.gov (dated 2026-07-29)

    In sportProhibited at all times. Named in S2.2.4 of the 2026 and 2027 Lists. WADA

  • Thymosin alpha-1

    Late-stage human trials

    FDA statusNot FDA-approved. Not on the US pharmacy compounding list. Approved in some other countries, including Italy. Source: fda.gov (dated 2026-04-22)

    In sportNot named on 2026 or 2027 Lists; approved in Italy, so outside S0. WADA

  • Tirzepatide

    Approved medicine

    FDA statusApproved prescription medicine (Mounjaro, Zepbound). Compounded and research-use versions are not approved. Source: fda.gov (dated 2026-10-01)

    In sportNot prohibited; approved, so outside S0. On the WADA Monitoring Program. WADA

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sign up and it opens right away.